>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Tubulysin F

Tubulysin F

Catalog No.GC37840

Tubulysin F는 점액박테리아 종 Archangium geophyra 및 Angiococcus disciformis에서 분리된 세포독성이 높은 펩티드입니다. Tubulysin은 더 낮은 나노몰 범위의 IC50 값으로 다중약물 내성 세포주를 포함한 포유동물 세포에서 매우 강력한 세포독성 활성을 나타냅니다. 튜불리신 F는 튜불린 중합을 억제하고 세포 주기 정지 및 세포자멸사를 유도하는 세포독성 활성 튜불리신이다.

Products are for research use only. Not for human use. We do not sell to patients.

Tubulysin F Chemical Structure

Cas No.: 368870-67-1

Size 가격 재고 수량
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tubulysin F is a highly cytotoxic peptide isolated from the myxobacterial species Archangium geophyra and Angiococcus disciformis. Tubulysin displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the lower nanomolar range[1]. Tubulysin F is a cytotoxic activity tubulysin which inhibits tubulin polymerization and leads to cell cycle arrest and apoptosis[2].

[1]. Kubicek K, et al. The tubulin-bound structure of the antimitotic drug tubulysin. Angew Chem Int Ed Engl. 2010 Jun 28;49(28):4809-12. [2]. Vlahov IR, et al. Acid mediated formation of an N-acyliminium ion from tubulysins: a new methodology for the synthesis of natural tubulysins and their analogs. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6778-81.

리뷰

Review for Tubulysin F

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tubulysin F

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.